Potency of tenofovir in chronic hepatitis B: Mono or combination therapy?

Journal of Hepatology

Volumn 48, Issue 3, 2008, Pages 383-386

  Reijnders, J G P ^a   Janssen, H L A ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ADEFOVIR DIPIVOXIL; EMTRICITABINE; ENTECAVIR; LAMIVUDINE; TELBIVUDINE; TENOFOVIR; TENOFOVIR DISOPROXIL;

ANTIVIRAL THERAPY; CHRONIC HEPATITIS; DISEASE COURSE; DRUG POTENCY; EDITORIAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MONOTHERAPY; PRIORITY JOURNAL; VIROTHERAPY; VIRUS INFECTION;

ADENINE; ANTIVIRAL AGENTS; DEOXYCYTIDINE; DNA, VIRAL; DRUG THERAPY, COMBINATION; GUANINE; HEPATITIS B; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; PHOSPHONIC ACIDS; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 39149091376     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2007.12.006     Document Type: Editorial

References (41)

1. Dienstag J.L., Cianciara J., Karayalcin S., Kowdley K.V., Willems B., Plisek S., et al. Durability of serologic response after lamivudine treatment of chronic hepatitis B. Hepatology 37 (2003) 748-755
2. Song B.C., Suh D.J., Lee H.C., Chung Y.H., and Lee Y.S. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology 32 (2000) 803-806
3. Shaw T., Bartholomeusz A., and Locarnini S. HBV drug resistance: mechanisms, detection and interpretation. J Hepatol 44 (2006) 593-606
4. Lok A.S., and McMahon B.J. Chronic hepatitis B. Hepatology 45 (2007) 507-539
5. Lok A.S., Zoulim F., Locarnini S., Bartholomeusz A., Ghany M.G., Pawlotsky J.M., et al. Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology 46 (2007) 254-265
6. Dienstag J.L., Goldin R.D., Heathcote E.J., Hann H.W., Woessner M., Stephenson S.L., et al. Histological outcome during long-term lamivudine therapy. Gastroenterology 124 (2003) 105-117
7. Liaw Y.F., Sung J.J., Chow W.C., Farrell G., Lee C.Z., Yuen H., et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 351 (2004) 1521-1531
8. Richman D.D. The impact of drug resistance on the effectiveness of chemotherapy for chronic hepatitis B. Hepatology 32 (2000) 866-867
9. Ghany M., and Liang T.J. Drug targets and molecular mechanisms of drug resistance in chronic hepatitis B. Gastroenterology 132 (2007) 1574-1585
10. Locarnini S. Hepatitis B viral resistance: mechanisms and diagnosis. J Hepatol 39 (2003) S124-S132
11. Lai C.L., Leung N., Teo E.K., Tong M., Wong F., Hann H.W., et al. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 129 (2005) 528-536
12. Locarnini S., Qi X., Arterburn S., Snow A., Brosgart C.L., Currie G., et al. Incidence and predictors of emergence of adefovir resistant HBV during 4 years of adefovir dipivoxil (ADV) therapy for patients with chronic hepatitis B (CHB). J Hepatol 42 (2005) 17
13. Yuen M.F., Sablon E., Hui C.K., Yuan H.J., Decraemer H., and Lai C.L. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology 34 (2001) 785-791
14. Tan J., Degertekin B., Wong S.N., Husain M., Oberhelman K., and Lok A.S.F. Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovir-resistant mutations. J Hepatol (2008) 10.1016/j.jhep.2007.09.020
15. Kramata P., Votruba I., Otova B., and Holy A. Different inhibitory potencies of acyclic phosphonomethoxyalkyl nucleotide analogs toward DNA polymerases alpha, delta and epsilon. Mol Pharmacol 49 (1996) 1005-1011
16. Hadziyannis S.J., Tassopoulos N.C., Heathcote E.J., Chang T.T., Kitis G., Rizzetto M., et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 348 (2003) 800-807
17. Marcellin P., Chang T.T., Lim S.G., Tong M.J., Sievert W., Shiffman M.L., et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 348 (2003) 808-816
18. Hadziyannis S.J., Tassopoulos N.C., Heathcote E.J., Chang T.T., Kitis G., Rizzetto M., et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 131 (2006) 1743-1751
19. Angus P., Vaughan R., Xiong S., Yang H., Delaney W., Gibbs C., et al. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 125 (2003) 292-297
20. Villeneuve J.P., Durantel D., Durantel S., Westland C., Xiong S., Brosgart C.L., et al. Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient. J Hepatol 39 (2003) 1085-1089
21. Borroto-Esoda K., Miller M.D., and Arterburn S. Pooled analysis of amino acid changes in the HBV polymerase in patients from four major adefovir dipivoxil clinical trials. J Hepatol 47 (2007) 492-498
22. Curtis M., Zhu Y., and Borroto-Esoda K. HBV rtI233V polymerase variant remains sensitive to adefovir. J Hepatol 46 (2007) A56
23. Lacombe K., Ollivet A., Gozlan J., Durantel S., Tran N., Girard P.M., et al. A novel hepatitis B virus mutation with resistance to adefovir but not to tenofovir in an HIV-hepatitis B virus-co-infected patient. AIDS 20 (2006) 2229-2231
24. Schildgen O., Sirma H., Funk A., Olotu C., Wend U.C., Hartmann H., et al. Variant of hepatitis B virus with primary resistance to adefovir. N Engl J Med 354 (2006) 1807-1812
25. Fung S.K., Chae H.B., Fontana R.J., Conjeevaram H., Marrero J., Oberhelman K., et al. Virologic response and resistance to adefovir in patients with chronic hepatitis B. J Hepatol 44 (2006) 283-290
26. Delaney W., Ray A.S., Yang H., Qi X., Xiong S., Zhu Y., et al. Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus. Antimicrob Agents Chemother 50 (2006) 2471-2477
27. Benhamou Y., Fleury H., Trimoulet P., Pellegrin I., Urbinelli R., Katlama C., et al. Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients. Hepatology 43 (2006) 548-555
28. Lacombe K., Gozlan J., Boelle P.Y., Serfaty L., Zoulim F., Valleron A.J., et al. Long-term hepatitis B virus dynamics in HIV-hepatitis B virus-co-infected patients treated with tenofovir disoproxil fumarate. AIDS 19 (2005) 907-915
29. Peters M.G., Andersen J., Lynch P., Liu T., Alston-Smith B., Brosgart C.L., et al. Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127. Hepatology 44 (2006) 1110-1116
30. Heathcote E.J., Gane E., De Man R., Lee S., Flisiak R., Manns M.P., et al. A randomized, double-blind, comparison of tenofovir DF (TDF) versus adefovir dipivoxil (ADV) for the treatment of HBeAg-positive chronic hepatitis B (CHB). Hepatology 46 (2007) S861A
31. Marcellin P., Buti M., Krastev Z., Germanidis G., Kaita K.D., Kotzev I., et al. A randomized, double-blind, comparison of tenofovir DF (TDF) versus adefovir dipivoxil (ADV) for the treatment of HBeAg-negative chronic hepatitis B (CHB). Hepatology 46 (2007) S290A-S291A
32. van Bommel F., Zollner B., Sarrazin C., Spengler U., Hüppe D., Möller B., et al. Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy. Hepatology 44 (2006) 318-325
33. van Bommel F., Trojan J., Feucht H., Möller B., Hüppe D., Wiedenmann B., et al. Tenofovir shows limited efficacy in treatment of HBV infections resistant against adefovir. Hepatology 46 (2007) S664A
34. Sheldon J., Camino N., Rodes B., Bartholomeusz A., Kuiper M., Tacke F., et al. Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir. Antivir Ther 10 (2005) 727-734
35. Brunelle M.N., Jacquard A.C., Pichoud C., Durantel D., Carrouée-Durantel S., Villeneuve J.P., et al. Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir. Hepatology 41 (2005) 1391-1398
36. Qi X., Xiong S., Yang H., Miller M., and Delaney W. In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents. Antivir Ther 12 (2007) 355-362
37. Villet S., Pichoud C., Villeneuve J.P., Trepo C., and Zoulim F. Selection of a multiple drug-resistant hepatitis B virus strain in a liver-transplanted patient. Gastroenterology 131 (2006) 1253-1261
38. Borroto-Esoda K., Vela J.E., Myrick F., Ray A.S., and Miller M.D. In vitro evaluation of the anti-HIV activity and metabolic interactions of tenofovir and emtricitabine. Antivir Ther 11 (2006) 377-384
39. Dore G.J., Cooper D.A., Pozniak A.L., DeJesus E., Zhong L., Miller M.D., et al. Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus. J Infect Dis 189 (2004) 1185-1192
40. Rapti I., Dimou E., Mitsoula P., and Hadziyannis S.J. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology 45 (2007) 307-313
41. Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Delta Coordinating Committee. Lancet 1996;348:283-291.